AptaBio Therapeutics (293780 KS) announced positive topline data for European phase 2 clinical trial of its lead candidate, APX-115, which is being developed for the treatment of diabetic nephropathy.
Future progress of APX-115 in clinical trial will depend much on AptaBio’s capacity to enter a licensing deal for APX-115 with global pharmaceutical companies.
The company’s other pipeline drugs are also progressing, thereby keeping R&D expenditures at elevated level. However, the company’s current cash balance is not sufficient fund its R&D expenditures for long-term.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.